KRAS and non-small cell lung carcinoma: Figure 2 shows the molecular profiles of patients diagnosed with advanced KRAS-mutant NSCLC classified based on gender, stage of disease, KRAS subtypes, smoking status, first-line treatment group, and PD-L1 expression.